A small study including 20 patients with CF, of which nine received Lumacaftor/Ivacaftor, the use of this CFTR modulator combination was associated with less hepatic steatosis as assessed by magnetic resonance imaging proton density fat fraction [58]. This evidence concerns the gene CFTR and cystic fibrosis.